Home

Selcaxen 40 mg (Selpercatinib)

Disclaimer: Before purchasing any medicine, always verify whether there is a valid drug license.

Selcaxen 40 mg is identified on this website as a product containing selpercatinib 40 mg. Selpercatinib is an orally administered targeted anticancer medicine that selectively inhibits the RET (rearranged during transfection) kinase.

RET is a receptor tyrosine kinase involved in cellular signaling. Certain RET gene fusions and mutations can produce abnormal RET signaling that contributes to uncontrolled cancer-cell growth. Selpercatinib is designed to inhibit these abnormal RET-driven pathways.

The established reference product for selpercatinib is RETEVMO, developed through Loxo Oncology, which became part of Eli Lilly and Company. FDA records identify Loxo Oncology, a wholly owned Lilly subsidiary, as the applicant/sponsor for RETEVMO, while the original U.S. approval of RETEVMO occurred in 2020.

For the specific Selcaxen 40 mg product, the manufacturer, marketing authorization holder, dosage form, country of authorization, packaging configuration and regulatory status should be confirmed against the actual product packaging and official product documentation.

Everest Pharmaceuticals Ltd. About the Manufacturer

Everest Pharmaceuticals Ltd. is a pharmaceutical manufacturer based in Bangladesh. The company is involved in the development, production, and marketing of pharmaceutical products, including medicines used in specialized therapeutic areas.
Everest Pharmaceuticals focuses on manufacturing quality medicines for the healthcare market and offers a range of products, including treatments used in oncology and other medical fields. Its product portfolio includes various generic medicines formulated for patients and healthcare providers.
Company Name: Everest Pharmaceuticals Ltd.
Industry: Pharmaceutical Manufacturing
Country: Bangladesh
Business Activities: Manufacturing, marketing, and distribution of pharmaceutical products
Product Areas: Includes specialized and general pharmaceutical medicines
Quality Focus: Product manufacturing and quality-control processes are intended to support medicine quality, safety, and regulatory compliance.
For product-specific information, it is important to check the official packaging, product insert, batch details, and manufacturer information, as formulations and regulatory status may vary by product and market.
Head Office: Everest Pharmaceuticals Ltd. is located at Rahman’s Regnum Centre (10th & 11th floor), 191/1 Tejgaon Commercial Area, Dhaka-1208, Bangladesh.
Manufacturing Plant: Everest Pharmaceuticals Limited B-33, 45 & 46, BSCIC, Kanchpur, Narayanganj–1430, Bangladesh.

Topic Information
Product name Selcaxen
Stated strength 40 mg
Active ingredient Selpercatinib
Drug class Selective RET kinase inhibitor
Therapeutic category Antineoplastic medicine
Route Oral, subject to Selcaxen-specific documentation
Reference product RETEVMO
Original development organization Loxo Oncology
Current reference-product company Eli Lilly and Company

Current U.S. RETEVMO labeling includes both capsules and tablets. The FDA documentation identifies 40 mg and 80 mg capsule strengths and tablet strengths of 40 mg, 80 mg, 120 mg and 160 mg. The existence of a 40 mg RETEVMO dosage form does not, by itself, establish the dosage form of Selcaxen 40 mg.

What Is Selcaxen 40 mg?

Selcaxen 40 mg is identified for this website as a medicine containing 40 mg of selpercatinib.

Selpercatinib is a selective RET kinase inhibitor used for cancers in which specific RET alterations are present. It belongs to the broader class of tyrosine kinase inhibitors.

Because the available Selcaxen-specific documentation does not establish all product characteristics, the website should distinguish between information known about the active ingredient selpercatinib and information specifically verified for the Selcaxen brand.

The active ingredient’s established reference medicine is RETEVMO. FDA records show that RETEVMO was initially approved in the United States in May 2020.

What Is Selpercatinib?

Selpercatinib is an oral targeted anticancer medicine that inhibits RET kinase.

RET alterations can act as oncogenic drivers in several cancers. These alterations may include:

By inhibiting abnormal RET signaling, selpercatinib can interfere with signaling pathways that contribute to cancer-cell growth and survival.

The European Medicines Agency describes selpercatinib as a RET inhibitor belonging to the broader tyrosine kinase inhibitor class.

How Does Selpercatinib Work?

Selpercatinib works primarily by inhibiting the activity of the RET kinase.

RET is normally involved in signaling between cells and contributes to cellular development and other physiological processes. In certain cancers, genetic alterations involving RET can produce abnormal signaling that promotes uncontrolled cell growth.

Selpercatinib binds to and inhibits RET kinase activity.

RET inhibition

The principal pharmacological action is inhibition of abnormal RET signaling.

This may interfere with:

Simple explanation

In simple terms, some cancers depend on abnormal RET signaling to grow. Selpercatinib is designed to block this signaling.

It is therefore considered a targeted therapy, rather than a conventional cytotoxic chemotherapy.

What Is Selcaxen Used For?

The approved uses of selpercatinib depend on the regulatory jurisdiction, cancer type, RET alteration and patient characteristics.

Current European authorization for Retsevmo includes selected:

The EMA states that Retsevmo is used as monotherapy in adults with advanced RET fusion-positive NSCLC who have not previously received a RET inhibitor, and in adults and pediatric patients aged 2 years and older for specified thyroid cancers and RET fusion-positive solid tumors.

Current U.S. FDA documentation likewise identifies RETEVMO as a treatment for specified RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, RET fusion-positive thyroid cancer and RET fusion-positive solid tumors.

The exact approved indication should always be checked against the prescribing information applicable to the patient’s country.

Selpercatinib for RET Fusion-Positive NSCLC

Selpercatinib is used in selected patients with RET fusion-positive non-small cell lung cancer (NSCLC).

RET fusions can create abnormal proteins that continuously activate RET signaling. In tumors dependent on this pathway, selective RET inhibition can interfere with the molecular signaling driving cancer growth.

Patient selection requires appropriate biomarker testing.

The FDA identifies RET gene fusion detection using an FDA-approved test as part of the U.S. indication.

Selpercatinib for Medullary Thyroid Cancer

Selpercatinib may be used for selected patients with RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy.

MTC can be associated with activating RET mutations. Blocking RET signaling provides a targeted therapeutic approach for patients whose tumors contain relevant RET alterations.

Age requirements and specific eligibility criteria differ according to jurisdiction and current labeling.

The EMA currently includes advanced RET-mutant medullary thyroid cancer among the authorized Retsevmo indications for patients from 2 years of age.

Selpercatinib for RET Fusion-Positive Thyroid Cancer

Selpercatinib can be used in selected patients with advanced thyroid cancer containing a RET gene fusion.

In the European authorization, treatment is directed toward advanced RET fusion-positive thyroid cancer that is radioactive-iodine refractory when radioactive iodine is appropriate.

Eligibility requirements should be confirmed from the applicable local prescribing information.

Selpercatinib for RET Fusion-Positive Solid Tumors

Selpercatinib also has a tissue-agnostic role in selected patients with RET fusion-positive solid tumors.

The EMA describes use in patients from 2 years of age when non-RET-targeting treatment options provide limited clinical benefit or have been exhausted.

The U.S. FDA has also authorized selpercatinib for certain adult patients with RET fusion-positive solid tumors that have progressed following systemic treatment or for whom satisfactory alternative treatment options are unavailable.

Reference Product: RETEVMO

The established reference brand for selpercatinib is RETEVMO in the United States and Retsevmo in the European Union.

RETEVMO contains selpercatinib and was initially approved by the U.S. FDA in 2020.

The FDA identifies Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, as the sponsor/applicant for RETEVMO.

The development history is therefore best described as follows:

Development aspect Information
Active ingredient Selpercatinib
Development organization Loxo Oncology
Current corporate relationship Loxo Oncology became part of Eli Lilly
Reference product RETEVMO / Retsevmo
Initial U.S. approval May 8, 2020
Current U.S. company relationship Eli Lilly and Company
EU marketing authorization holder Eli Lilly Nederland B.V.

The EMA currently lists Eli Lilly Nederland B.V. as the marketing authorization holder for Retsevmo in the European Union.

Important distinction

The reference-product developer and manufacturer should not automatically be identified as the manufacturer of Selcaxen.

A product can contain the same active ingredient as the reference medicine while being manufactured by another pharmaceutical company under a separate authorization.

For this reason:

Selcaxen manufacturer: [Information requires verification]

should remain in place until supported by official Selcaxen documentation.

Selcaxen vs RETEVMO

Selcaxen and RETEVMO should not automatically be described as identical products simply because they contain selpercatinib.

Characteristic Selcaxen 40 mg RETEVMO
Active ingredient Selpercatinib Selpercatinib
Stated strength 40 mg 40 mg dosage form exists in U.S. labeling
Product status Requires product-specific verification Established reference product
Original development organization Not applicable to Selcaxen unless documented Loxo Oncology
Current corporate relationship Requires verification Eli Lilly
Manufacturer Requires verification Refer to current official labeling
Regulatory authorization Requires verification Established in applicable jurisdictions
Formulation Requires verification Capsules/tablets depending on market and labeling

The active ingredient may be the same, while excipients, formulation, manufacturing site, packaging, authorization pathway and commercial ownership can differ.

Available Strength

Selcaxen is identified for this website as 40 mg.

The 40 mg figure refers to the stated amount of selpercatinib associated with the product.

It should not be assumed that Selcaxen is available in other strengths unless those strengths are confirmed by official Selcaxen product documentation.

The reference product RETEVMO has multiple dosage forms and strengths, but those reference-product characteristics should not automatically be transferred to Selcaxen.

How Selpercatinib Is Taken

Selpercatinib is an oral medicine.

Administration instructions can depend on the formulation and current regulatory labeling. The European Medicines Agency describes Retsevmo as available as capsules and tablets taken by mouth, with dosing dependent on factors including age and body weight.

Patients should:

For Selcaxen specifically, administration instructions should be confirmed from the official product documentation.

Dosage and Administration

Selpercatinib dosing is not determined solely by the product strength.

The appropriate regimen can depend on:

A 40 mg dosage unit should therefore not be interpreted as an instruction to take a particular number of units per day.

Important

The appropriate dose must be prescribed by a qualified healthcare professional based on the applicable prescribing information.

Do not use this website to determine an individualized cancer-treatment dose.

Missed Dose

Missed-dose instructions should be taken from the official prescribing information for the specific selpercatinib product being used.

Patients should not automatically take extra medication to compensate for a missed dose.

If a dose is missed, patients should follow the product leaflet or contact their treating healthcare professional or pharmacist when the correct procedure is uncertain.

Selpercatinib Side Effects

Selpercatinib can cause adverse reactions ranging from relatively manageable effects to clinically significant complications.

Potential adverse reactions may include:

The frequency and severity of adverse reactions can vary according to the patient population, dose, cancer type and concomitant treatment.

Important Serious Risks

Selpercatinib treatment requires appropriate medical supervision.

Important safety concerns associated with selpercatinib include:

Risk Clinical concern
Hepatotoxicity Liver injury and elevated liver enzymes
Interstitial lung disease/pneumonitis Potentially serious lung inflammation
Hypertension Clinically significant elevation in blood pressure
QT interval prolongation Potential cardiac rhythm risk
Hemorrhagic events Potentially serious bleeding
Hypersensitivity Allergic or immune-mediated reactions
Hypothyroidism Altered thyroid function
Diarrhea May become clinically significant
Electrolyte abnormalities May require monitoring and correction

Patients should report concerning or persistent symptoms promptly to their healthcare professional.

Hepatotoxicity

Selpercatinib can cause liver toxicity.

Liver-function testing may therefore be required during treatment.

Patients should promptly report symptoms that could indicate significant liver problems, such as:

The treating healthcare professional may modify, interrupt or discontinue treatment depending on the severity of liver toxicity.

Interstitial Lung Disease and Pneumonitis

Selpercatinib has been associated with interstitial lung disease/pneumonitis.

Potential warning symptoms can include:

New respiratory symptoms during treatment should be assessed promptly.

Hypertension

Selpercatinib can cause elevated blood pressure.

Blood pressure monitoring may therefore be necessary during treatment.

Patients with significant hypertension may require medical treatment and, depending on severity, modification of selpercatinib therapy.

QT Interval Prolongation

Selpercatinib can prolong the QT interval, which can increase the risk of abnormal heart rhythms in susceptible patients.

Healthcare professionals may consider:

Patients should inform their healthcare professional about other medicines and supplements they use.

Hemorrhagic Risk

Hemorrhagic events can occur with selpercatinib treatment.

Patients should promptly report unusual or significant bleeding.

Examples include:

Serious bleeding requires immediate medical evaluation.

Thyroid Function

Selpercatinib can affect thyroid function.

Patients may require thyroid-function monitoring during therapy, particularly when there is an existing thyroid disorder or when the patient is being treated for thyroid cancer.

Drug Interactions

Selpercatinib can interact with other medicines.

A complete medication review is important before and during treatment.

Potentially relevant medicines may include:

Patients should provide their healthcare professional with a complete list of prescription medicines, over-the-counter medicines, vitamins and supplements.

Pregnancy and Reproductive Considerations

Selpercatinib may cause fetal harm.

Patients who are pregnant, planning pregnancy or who could become pregnant should discuss treatment with their healthcare professional before taking selpercatinib.

Pregnancy-prevention requirements can depend on the patient’s circumstances and applicable prescribing information.

Breastfeeding

Breastfeeding recommendations should be taken from the current official prescribing information applicable to the selpercatinib product.

Patients should discuss breastfeeding with their healthcare professional before starting treatment.

Monitoring During Treatment

Monitoring may include, depending on the patient and treatment indication:

The precise monitoring schedule should be determined by the treating healthcare professional.

Clinical Pharmacology

Selpercatinib is a selective RET kinase inhibitor.

Its pharmacological activity is directed toward abnormal RET signaling associated with RET-driven cancers.

Unlike conventional chemotherapy, which generally affects rapidly dividing cells more broadly, selpercatinib is designed to target a specific molecular pathway.

This biomarker-directed approach makes appropriate molecular testing important when considering selpercatinib therapy.

Biomarker Testing

Treatment with selpercatinib generally requires identification of a relevant RET alteration.

Depending on the disease, testing may identify:

The testing method should meet the requirements of the applicable regulatory indication.

A diagnosis of cancer alone does not establish that selpercatinib is appropriate.

Everest Pharmaceuticals Ltd. Product Verification Process

To verify the authenticity of an Everest Pharmaceuticals product, follow the verification process below:
Scan the QR Code: Scan the QR code printed on the product box.
The QR code will direct you to the official product verification page.
Open the Box: After accessing the verification page, open the product box and locate the verification code printed on the bottle.
Submit the Verification Code: Enter the verification code from the bottle on the verification page and submit it to check the product’s authenticity.
Verification Success: If the verification is successful, the product is confirmed as legitimate.
Verification Error: If the system displays a verification error, the product may be counterfeit or unauthorized. Do not use the product until its authenticity has been confirmed through an appropriate official channel.
Counterfeit Products: If a product is confirmed to be fake, do not use or distribute it. Report the suspected counterfeit product and supplier to the appropriate regulatory authorities, such as the Directorate General of Drug Administration (DGDA) in World, and take appropriate legal action against the supplier through the relevant authorities.
Important: Always purchase medicines from licensed pharmacies or authorized suppliers and verify suspicious products before use.

Authentication

No specific Selcaxen QR-code verification service, online authentication portal or batch-checking system should be claimed unless it is documented by the manufacturer or relevant regulator.

If packaging appears suspicious or damaged, the product should be checked with a pharmacist, authorized supplier or appropriate regulatory authority before use.

Manufacturer and Originator Information

Who Developed Selpercatinib?

Selpercatinib was developed through Loxo Oncology.

Loxo Oncology became part of Eli Lilly and Company, and FDA records identify Loxo Oncology as a wholly owned subsidiary of Eli Lilly in connection with RETEVMO development and regulatory submissions.

Lilly’s current oncology materials list Retevmo (selpercatinib) among its cancer products.

Reference Product

The principal reference product is RETEVMO in the United States and Retsevmo in the European Union.

The EMA currently lists Eli Lilly Nederland B.V. as the marketing authorization holder for Retsevmo in the European Union.

Selcaxen Manufacturer

The specific manufacturer of Selcaxen 40 mg is: Everest Pharmaceuticals Ltd.

This should not be replaced with Eli Lilly or Loxo Oncology unless official Selcaxen documentation establishes such a relationship.

Manufacturer vs Originator vs Marketing Authorization Holder

These pharmaceutical terms describe different roles.

Originator / Developer

The organization responsible for discovering and developing the medicine or reference product.

For selpercatinib, the development history is associated with Loxo Oncology, subsequently part of Eli Lilly.

Manufacturer

The company or facility responsible for manufacturing the particular medicinal product.

For Selcaxen:

[Information requires verification]

Marketing Authorization Holder

The legal entity responsible for a medicinal product’s authorization in a particular jurisdiction.

For EU Retsevmo, the EMA identifies Eli Lilly Nederland B.V. as the marketing authorization holder.

Distributor

An entity responsible for distributing a product through a commercial supply chain.

Supplier

The party supplying the medicine through a particular commercial channel.

These roles may belong to different organizations.

Regulatory Status

The regulatory status of Selcaxen 40 mg is:

[Information requires verification]

The existence of an approved selpercatinib reference product does not establish regulatory approval for a separately branded product.

Any statement about Selcaxen’s approval, registration, marketing authorization or legal availability should be supported by the relevant national regulatory authority or official manufacturer documentation.

Important Product Identity Statement

Selcaxen should not be described as RETEVMO unless the specific legal and regulatory relationship is documented.

The appropriate wording is:

Selcaxen is identified on this website as a product containing selpercatinib 40 mg. RETEVMO is the established reference product containing selpercatinib.

The two products may contain the same active pharmaceutical ingredient while differing in manufacturer, formulation, excipients, packaging and authorization status.

Frequently Asked Questions

What is Selcaxen 40 mg?

Selcaxen 40 mg is identified on this website as a product containing 40 mg of selpercatinib, a selective RET kinase inhibitor. Product-specific manufacturer and regulatory details require verification.

What is selpercatinib?

Selpercatinib is an oral targeted anticancer medicine that selectively inhibits RET kinase.

What is selpercatinib used for?

Selpercatinib is used for selected RET-driven cancers, including certain RET fusion-positive lung and thyroid cancers, RET-mutant medullary thyroid cancer and selected RET fusion-positive solid tumors. Approved indications differ by jurisdiction.

What is the reference product for selpercatinib?

The established reference product is RETEVMO, marketed as Retsevmo in the European Union.

Who developed selpercatinib?

Selpercatinib was developed through Loxo Oncology, which became part of Eli Lilly and Company.

Who manufactures Selcaxen?

The specific manufacturer of Selcaxen 40 mg requires verification against official Selcaxen product documentation.

Is Selcaxen the same as RETEVMO?

It should not automatically be described as identical to RETEVMO merely because both contain selpercatinib. Manufacturer, formulation, excipients, packaging and authorization may differ.

Is selpercatinib chemotherapy?

Selpercatinib is generally classified as a targeted anticancer therapy and selective RET tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.

How does selpercatinib work?

It inhibits RET kinase signaling, including abnormal signaling associated with RET gene fusions and mutations.

Does selpercatinib require biomarker testing?

Treatment selection generally depends on identification of a relevant RET alteration. The testing requirements depend on the specific indication and jurisdiction.

What are important selpercatinib side effects?

Important safety concerns include hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT prolongation, hemorrhagic events and thyroid-function abnormalities.

Can selpercatinib affect the heart?

Yes. QT interval prolongation is an important safety consideration and may require appropriate monitoring.

Can selpercatinib affect the liver?

Yes. Hepatotoxicity can occur, and liver-function monitoring may be required.

Can selpercatinib cause high blood pressure?

Yes. Hypertension is a recognized adverse reaction and blood pressure may require monitoring during treatment.

Is Selcaxen 40 mg approved?

The regulatory status of the specific Selcaxen 40 mg product requires verification. Approval of RETEVMO does not by itself establish approval of Selcaxen.

Where can Selcaxen be purchased?

Availability and lawful supply depend on the country, product authorization and applicable prescription requirements. Product-specific ordering and distribution information requires verification.

Medical Information Disclaimer

The information published on this page is intended for general educational and informational purposes.

It does not replace official prescribing information, professional medical assessment or individualized treatment advice.

Selpercatinib is a prescription anticancer medicine and should be used under the supervision of an appropriately qualified healthcare professional.

Do not start, stop, increase, decrease or otherwise change cancer treatment based solely on information presented on this website.

Approved indications, dosage recommendations, safety warnings, age requirements and regulatory status may differ between countries and may change as regulatory authorities update product information.

For Selcaxen specifically, manufacturer, authorization, formulation, packaging and other product-specific claims should be verified against official documentation.

References

U.S. Food and Drug Administration — RETEVMO

FDA prescribing information establishes RETEVMO as selpercatinib and provides information concerning indications, dosage forms, safety and clinical use.

FDA Regulatory Review

FDA review documents identify Loxo Oncology as the applicant for RETEVMO tablets and describe Loxo Oncology as a wholly owned subsidiary of Eli Lilly and Company.

FDA Orphan Drug Database

FDA records identify Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, as the sponsor associated with selpercatinib/RETEVMO orphan-drug designations and approvals.

European Medicines Agency — Retsevmo

The EMA provides current European information concerning selpercatinib, including authorized indications, dosage forms and the EU marketing authorization holder.

Eli Lilly
Lilly’s current product information identifies Retevmo as a selpercatinib cancer medicine.
Daniel M
Very helpful information about Selcaxen 40 mg and selpercatinib. The explanation of RET-targeted treatment and the important safety considerations was clear and easy to understand.
Sarah K.
I found the Selcaxen information well organized and useful. The sections about dosage, side effects, genetic testing, and drug interactions made it easier to understand what should be discussed with a healthcare professional.
Michael R
Clear and informative resource about selpercatinib. I especially appreciated the explanation of RET mutations and fusions, along with the information about monitoring and potential side effects.

Latest News

FAQs

Tell your doctor about all medicines, supplements, medical conditions and previous treatment you are receiving. It is especially important to discuss liver problems, high blood pressure, heart rhythm problems and any medicines that may interact with selpercatinib.

Yes. Selpercatinib can interact with certain medicines, including some CYP3A inhibitors or inducers, acid-reducing medicines and medicines that may affect heart rhythm. Your healthcare professional should review your complete medication list before and during treatment.

Storage requirements should be confirmed from the official product information supplied with Selcaxen 40 mg. Because the specific Selcaxen formulation and manufacturer require verification, do not assume that storage conditions are identical to another selpercatinib product.

Follow the missed-dose instructions provided with your prescription and official product information. Do not take an extra dose to compensate unless your healthcare professional specifically instructs you to do so.

Current U.S. labeling includes selpercatinib for certain RET-mutant or RET fusion-positive cancers in pediatric patients aged 2 years and older. Pediatric dosing is based on body-surface area and requires specialist medical supervision.

Selpercatinib can cause or worsen hypertension. Regular blood-pressure monitoring helps healthcare professionals identify significant increases early and determine whether treatment or blood-pressure management needs to be adjusted.

Selpercatinib can cause increases in liver enzymes and clinically significant hepatotoxicity. Liver-function monitoring can help identify abnormalities early so that appropriate medical management can be considered.

A RET fusion-positive cancer contains a genetic rearrangement involving the RET gene that can produce abnormal RET signaling. Identifying a relevant RET fusion can help determine whether a RET-targeted treatment such as selpercatinib may be appropriate.

RET-mutant medullary thyroid cancer is a form of medullary thyroid cancer in which a clinically relevant mutation in the RET gene is present. Selpercatinib is used for selected patients with advanced or metastatic RET-mutant disease under applicable labeling.

New or worsening shortness of breath, cough or fever should be reported promptly to a healthcare professional because selpercatinib can cause interstitial lung disease or pneumonitis. Serious cases may require immediate medical evaluation and treatment adjustment.